Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example

ABSTRACT The effects of several antimicrobial agents are predicted by the ratio of the area under the concentration-time curve (AUC) to the MIC (AUC/MIC). Peak (Cp) and trough (Ct) concentrations are often measured clinically as surrogates of AUC because actual computation of AUC from 1 or 2 samples requires sophisticated mathematical methods. Given that the effects of daptomycin are predicted by AUC/MIC, our objective was to compare simple equation calculated AUC based on Cp and Ct to model integrated AUC. A standard population pharmacokinetic model was used to simulate 5,000 daptomycin concentration-time profiles after 5 doses of 6 mg/kg of body weight/day (0.5-h infusions). The AUC for the 24-h period was computed by integration and by equations with 110 Cp-Ct combination pairs. The Cp time points were in 15-min increments between 0.5 h and 3 h and Ct in 15-min increments within an hour of the end of the dosing interval for each dose. The precision and bias of the calculated AUC relative to the integrated AUC were determined to identify Cp-Ct pairs associated with the lowest bias and highest precision. The equations were further validated using two daptomycin concentration-time data sets from healthy volunteers and critically ill patients. The precision and bias of calculated AUC were based primarily on Cp, and use of a daptomycin Cp 1.5 h to 3 h from the start of infusion was associated with a bias of <10% and an R2 of >0.95. Data from the healthy volunteers and critically ill patients also demonstrated declining bias with use of Cp ≥1.5 h from the start of infusion with relatively good precision. Simplified equations using a daptomycin Cp approximately 2 h from the start of infusion and a Ct within an hour of the end of the dosing interval should yield precise and unbiased estimates of daptomycin AUC.

[1]  K. Rodvold,et al.  Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. , 2014, Diagnostic microbiology and infectious disease.

[2]  M. Bassetti,et al.  Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia , 2014, Infection.

[3]  F. D. De Rosa,et al.  Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. , 2014, Journal of pharmaceutical and biomedical analysis.

[4]  M. Falcone,et al.  Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Guan-Yuan Chen,et al.  Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. , 2013, Talanta.

[6]  J. Roberts,et al.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill , 2013, Intensive Care Medicine.

[7]  M. Karlsson,et al.  Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. , 2013, International journal of antimicrobial agents.

[8]  Roland Jw Meesters,et al.  State-of-the-art dried blood spot analysis: an overview of recent advances and future trends. , 2013, Bioanalysis.

[9]  G. Drusano,et al.  Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target , 2012, Antimicrobial Agents and Chemotherapy.

[10]  F. Pea,et al.  TDM-Guided Therapy with Daptomycin and Meropenem in a Morbidly Obese, Critically Ill Patient , 2011, The Annals of pharmacotherapy.

[11]  G. Drusano,et al.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. H. Baltz,et al.  Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Norenberg,et al.  Influence of Morbid Obesity on the Single-Dose Pharmacokinetics of Daptomycin , 2007, Antimicrobial Agents and Chemotherapy.

[14]  M. Barclay,et al.  A suggested approach to once-daily aminoglycoside dosing. , 1995, British journal of clinical pharmacology.

[15]  R W Jelliffe,et al.  Modeling, adaptive control, and optimal drug therapy. , 1990, Medical progress through technology.

[16]  R. Sawchuk,et al.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients , 1976, Journal of Pharmacokinetics and Biopharmaceutics.

[17]  G. d’Ettorre,et al.  Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[18]  J. Roberts,et al.  Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. , 2011, Critical care clinics.

[19]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.